Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Argueta LB, Lacko LA, Bram Y, Tada T, Carrau L, Zhang T, et al. SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta. bioRxiv. 2021.

Narayanan D, Pozdnyakova O, Hasserjian RP, Patel SS, Weinberg OK. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Adv. 2021;5(11):2539-2549.

Wang J, Hu H, Liu X, Zhao S, Zheng Y, Jia Z, et al. Predictive values of various serum biomarkers in women with suspected preeclampsia: A prospective study. J Clin Lab Anal. 2021;35(5):e23740.

Nix JS, Yuan M, Imada EL, Ames H, Marchionni L, Gutmann DH, et al. Global microRNA profiling identified miR-10b-5p as a regulator of neurofibromatosis 1 (NF1)-glioma migration. Neuropathol Appl Neurobiol. 2021;47(1):96-107.

Crawford JM, Aguero-Rosenfeld ME, Aifantis I, Cadoff EM, Cangiarella JF, Cordon-Cardo C, et al. The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. Acad Pathol. 2021;8:23742895211006818.

Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, et al. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(4):751-756.

Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun. 2021;12(1):1117.

Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021;589(7841):270-275.

Sakunrangsit N, Pholtaisong J, Sucharitakul J, Wanna-Udom S, Prombutara P, Pisitkun P, et al. Identification of candidate regulators of mandibular bone loss in FcγRIIB Mice. Sci Rep. 2021;11(1):18726.

Petroni G, Buqué A, Yamazaki T, Bloy N, Di Liberto M, Chen-Kiang S, et al. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. Clin Cancer Res. 2021;27(7):1855-1863.